Zhang Jinyin, Tan Qingquan, Fan Yang, Xiao Liu, Zheng Zhenjiang, Li Keyu, Jing Wenyi, Song Haiyu, Liu Xubao, Tan Chunlu, Wang Xing
Division of Pancreatic Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Eur J Radiol. 2025 Jun;187:112095. doi: 10.1016/j.ejrad.2025.112095. Epub 2025 Apr 6.
This study aims to evaluate the effectiveness of contrast-enhanced computed tomography (CT) in distinguishing non-hypervascular pancreatic neuroendocrine neoplasms (PNENs) from pancreatic ductal adenocarcinomas (PDACs) with a normal serum level of carbohydrate antigen 19-9 (CA19-9) levels.
This retrospective study included 134 patients with pathologically confirmed non-hypervascular PNENs and 128 patients with CA19-9-negative PDACs, all of whom underwent contrast-enhanced CT prior to surgery between January 2015 and March 2024. Following independent evaluation by two radiologists, qualitative features from both groups were extracted in the arterial and portal venous phase and subsequently compared using univariate and multivariate analysis.
Patients with CA19-9 negative PDACs were significantly older than those with non-hypervascular PNENs (p < 0.001), and the majority of PDACs were located in the head of the pancreas (p < 0.01).Univariate analysis showed that non-hypervascular PNENs exhibited a higher frequency of well-defined tumor margins (p < 0.001) and calcification (p = 0.032) and a lower frequency of local invasion (p < 0.001), peripancreatic vascular invasion (p = 0.001), intra- or extrahepatic bile duct dilatation (p < 0.001), distal main pancreatic duct dilatation (p < 0.001), regional lymphadenopathy (p < 0.001) and tumor homogeneity (p < 0.001) when compared to CA19-9 negative PDACs. Multivariate analysis identified the absence of local invasion (Odds Ratio (OR) = 0.233; 95 % Confidence Internals (95 % CI):0.114-0.476; p < 0.001), absence of peripancreatic vascular invasion (OR = 0.434; 95 % CI:0.217-0.870; p = 0.019), a normal distal main pancreatic duct diameter (OR = 0.398; 95 % CI:0.202-0.785; p = 0.008), absence of regional lymphadenopathy (OR = 0.455; 95 % CI:0.238-0.870; p = 0.017) and tumor heterogeneity (OR = 0.240; 95 % CI:0.126-0.456; p < 0.001) as significant predictors of non-hypervascular PNENs. The area under the receiver operating characteristic curve for the radiological feature model was 0.829 based on logistic regression.
Qualitative features in contrast-enhanced CT images could be beneficial in differentially diagnosing non-hypervascular PNENs and CA19-9 negative PDACs.
本研究旨在评估对比增强计算机断层扫描(CT)在鉴别血清糖类抗原19-9(CA19-9)水平正常的非高血供胰腺神经内分泌肿瘤(PNENs)与胰腺导管腺癌(PDACs)中的有效性。
本回顾性研究纳入了134例经病理证实的非高血供PNENs患者和128例CA19-9阴性的PDACs患者,所有患者在2015年1月至2024年3月手术前均接受了对比增强CT检查。在两名放射科医生独立评估后,提取两组在动脉期和门静脉期的定性特征,随后进行单因素和多因素分析比较。
CA19-9阴性的PDACs患者比非高血供PNENs患者年龄显著更大(p<0.001),且大多数PDACs位于胰头(p<0.01)。单因素分析显示,与CA19-9阴性的PDACs相比,非高血供PNENs表现出更高的肿瘤边界清晰频率(p<0.001)和钙化频率(p=0.032),以及更低的局部侵犯频率(p<0.001)、胰周血管侵犯频率(p=0.001)、肝内或肝外胆管扩张频率(p<0.001)、主胰管远端扩张频率(p<0.001)、区域淋巴结肿大频率(p<0.001)和肿瘤同质性频率(p<0.001)。多因素分析确定无局部侵犯(比值比(OR)=0.233;95%置信区间(95%CI):0.114-0.476;p<0.001)、无胰周血管侵犯(OR=0.434;95%CI:0.217-0.870;p=0.019)、主胰管远端直径正常(OR=0.398;95%CI:0.202-0.785;p=0.008)、无区域淋巴结肿大(OR=0.455;95%CI:0.238-0.870;p=0.017)和肿瘤异质性(OR=0.240;95%CI:0.126-0.456;p<0.001)是非高血供PNENs的显著预测因素。基于逻辑回归的放射学特征模型的受试者工作特征曲线下面积为0.829。
对比增强CT图像中的定性特征有助于鉴别非高血供PNENs和CA19-9阴性的PDACs。